<DOC>
	<DOCNO>NCT00311155</DOCNO>
	<brief_summary>This study ass safety efficacy add-on treatment algorithm olmesartan , hydrochlorothiazide amlodipine patient mild moderate hypertension .</brief_summary>
	<brief_title>Olmesartan add-on Treatment Patients With Mild Moderate Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Olmesartan</mesh_term>
	<mesh_term>Olmesartan Medoxomil</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Male female patient age great equal 18 year mild moderate hypertension . Pretreated patient normal elevate blood pressure ( BP ) eligible participate pretreatment medication withdrawn . At end placebo runin period sit systolic BP great equal 140 less 180 mmHg and/or sit diastolic BP great equal 90 less 110 mmHg trough . Female patient childbearing potential must pregnant lactating must use adequate contraception . Patients serious disorder may limit ability evaluate efficacy safety test drug ( ) , include cardiovascular , renal , pulmonary , hepatic , gastrointestinal , endocrine/metabolic , haematological/oncological , neurological psychiatric disease . Patients within last 6 month history myocardial infarction , unstable angina pectoris , percutaneous coronary intervention , heart failure , cerebrovascular accident , transient ischemic attack . Patients clinically significant elevation laboratory value Screening Visit . Patients secondary hypertension etiology , renal disease , pheochromocytoma , Cushing 's syndrome . Patients contraindication olmesartan medoxomil , hydrochlorothiazide , and/or amlodipine besylate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Olmesartan medoxomil</keyword>
	<keyword>Hypertension</keyword>
</DOC>